A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers
Latest Information Update: 09 Jan 2024
At a glance
- Drugs MEDI 0618 (Primary) ; MEDI 0618 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Jan 2024 Status changed from active, no longer recruiting to completed.
- 20 Nov 2023 Planned End Date changed from 26 Dec 2023 to 7 Dec 2023.
- 20 Nov 2023 Planned primary completion date changed from 26 Dec 2023 to 7 Dec 2023.